the risk of viral transmission together with a shortage in blood supplies has focused attention on the development of human blood substitutes new jersey-based biotechnology company enzon has now been granted a patent for its red blood cell substitute which uses bovine cow haemoglobin the haemoglobin is modified by attaching hair-like strands of the polymer polyethylene glycol peg to the protein in order to reduce its recognition by the body's immune system this peg-haemoglobin circulates longer in the body producing fewer allergic reactions peg-haemoglobin also eliminates the need for blood typing and matching enzon us 908 980 4500